TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02399137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Study: NCT02764658

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine care on the stable COPD
Description: To investigate whether daily physical activity、hypoxia and hyperinflation were associated with airway inflammation and PRG4 in Non-Pulmanary recovery patients wtih stable COPD.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine care on the stable COPD
Description: To investigate whether daily physical activity、hypoxia and hyperinflation were associated with airway inflammation and PRG4 in Non-Pulmanary recovery patients wtih stable COPD.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine care on the stable COPD
Description: To investigate whether daily physical activity、hypoxia and hyperinflation were associated with airway inflammation and PRG4 in Non-Pulmanary recovery patients wtih stable COPD.
Study: NCT01923662

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IST-16 (16-Channel implanted stimulator-telemeter
Description: Surgical implantation of IST-16 stimulator and electrodes to stimulate paralyzed muscles. Subjects will receive exercise and physical therapy with the implanted device. Functional training and laboratory assessments of clinical and technical performance will be conducted.
Study: NCT01322347

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Soluble Ferric Pyrophosphate (SFP)
Description: Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 18 months.
Study: NCT02116452

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplemented Formula
Description: 50:50 mixture of GOS/PDX formula will be administered
Study: NCT03781440

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bilateral ESP catheter with lidocaine
Description: All participants will get the Erector Spinae Plane (ESP) catheters. Prior to transfer to the operating room, participants will receive bilateral ESP catheters at T7 level under ultrasound guidance. This arm is the treatment group and will receive lidocaine via alternating side automated infusion pump bolus dosing, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Bilateral ESP catheter with saline
Description: All participants will get the Erector Spinae Plane (ESP) catheters. This arm is the control group and will have normal saline administered via ESP catheters, continued until chest tube removal or postoperative day 5 (whichever occurs earliest).
Study: NCT03505203

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep Soothe
Description: An intervention in which parents are given information on how to respond to their baby's cues related to sleeping and fussiness.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Safe
Description: An intervention in which parents are given information on a safe sleep environment, as well as other strategies to keep baby safe.
Study: NCT02694900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manually chest compressions
Description: Chest compressions performed manually without any device
Study: NCT02315716

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous Stem Cell Transplant (ASCT)
Description: Randomisation to melphalan conditioned autologous stem cell transplant
Study: NCT02694900

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manually chest compressions
Description: Chest compressions performed manually without any device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiopump
Description: Chest compressions performed with Cardiopump

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiopump
Description: Chest compressions performed with Cardiopump

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeLine ARM
Description: Chest compressions performed using mechanical chest compressions system LifeLine ARM

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeLine ARM
Description: Chest compressions performed using mechanical chest compressions system LifeLine ARM
Study: NCT02105038

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinner knob

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Knob
Study: NCT00606619

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Conventional feeding
Description: Procedure of Conventional feeding group: Patients are supplied water on day 3 after operation, liquid diet on day 4 and 5 and soft diet on 6 day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early oral feeding
Description: Procedure of Early oral feeding group: Patients are supplied water on day 1 after operation, liquid diet on day 2 and soft diet on day 3 day.
Study: NCT03019718

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GSA-Online plus
Description: A 12-week online writing intervention based on the Core Conflictual Relationship Theme Method (CCRT) with feedback provided by online therapists.
Study: NCT01351961

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood sampling
Description: take a sample of blood, 46 ml

Intervention type: PROCEDURE
Group type: OTHER
Intervention: brain MRI and TEP cerebral
Description: magnetic resonance imaging

Intervention type: OTHER
Group type: OTHER
Intervention: Assessment of cognitive functions
Description: Folstein MMSE, Mac Nair scale, Depression (GDS) scale, The Benton Visual Retention Test, Test of verbal fluency, formal and categorical, Trail Making Test, Grober et Buschke scale (RL/RI-16), Apathy Robert scale, Praxis rating Scale .

Intervention type: OTHER
Group type: OTHER
Intervention: Electrocardiogram and blood pressure
Description: Electrocardiogramm Blood pressure monitoring

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Vascular explorations
Description: Pulse wave velocity, VWF, IMT
Study: NCT02667483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5141b
Description: DS-5141b, Subcutaneous injection
Study: NCT00422032

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Group A: 15 mg/m\^2 IV over 1 hour daily for 5 days~Group B: 30 mg/m\^2 IV over 1 hour daily for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofarabine
Description: Group A: 15 mg/m\^2 IV over 1 hour daily for 5 days~Group B: 30 mg/m\^2 IV over 1 hour daily for 5 days
Study: NCT03283020

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RemifentanilMNTX
Description: Remifentanil infusion TCI 3 ng/ml, Methylnaltrexone injection 0.3 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PlaceboMNTX
Description: Placebo (NaCl 0.9%) TCI infusion, Methylnaltrexone injection 0.3 mg/kg
Study: NCT02812758

Intervention type: DEVICE
Intervention: transthoracic echocardiography
Description: recording of data on cardiac output measured non-invasively by transthoracic echocardiography, including the SVV
Study: NCT00497536

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart (IAsp)
Description: IAsp 100 U.~≈ bolus protocol: From 6 pm until 6 am~• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)~From 8 am until 6 pm~1 dose/h + 50 % s.c. (≈ bolus).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart (IAsp).
Description: IAsp 100 U From 6 pm until 8 am~• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)~From 8 am until 6 pm 50 % increase of basal rate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Aspart (IAsp)
Description: IAsp 100 U From 6 pm until 8 am~• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)~From 8 am until 6 pm 50 % increase of basal rate
Study: NCT01589081

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Nicotine
Description: Subjects will be given an IV challenge dose of nicotine or placebo in a constant volume of 2 mL on any study session day. The nicotine solutions (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (2 mL over one minute) has been safe in our IRB-approved studies of nicotine. Most investigators have administered nicotine over 10 seconds without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg; and 1.5 mg/70kg) will be administered first and the higher dose (2.0 mg/70kg) will be administered last.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Nicotine
Description: Subjects will be given an IV challenge dose of nicotine or placebo in a constant volume of 2 mL on any study session day. The nicotine solutions (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (2 mL over one minute) has been safe in our IRB-approved studies of nicotine. Most investigators have administered nicotine over 10 seconds without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg; and 1.5 mg/70kg) will be administered first and the higher dose (2.0 mg/70kg) will be administered last.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: To stimulate the luteal phase of the menstrual cycle, Prometrium capsules containing 200 mg of micronized progesterone or placebo (lactose containing) capsules will be administered orally at 120 minutes before the injection of IV nicotine.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: To stimulate the luteal phase of the menstrual cycle, Prometrium capsules containing 200 mg of micronized progesterone or placebo (lactose containing) capsules will be administered orally at 120 minutes before the injection of IV nicotine.
Study: NCT00799968

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urokinase
Description: UK,bolus 4 400 U/kg followed by intravenous 2 200 U/kg•h for 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urokinase
Description: UK,20 000U/kg continuously intravenous infusion for 2 hours
Study: NCT02315716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Consolidation with 4 cycles of CarCyDex
Description: Randomisation to 4 further cycles of Carfilzomib, Cyclophosphamide and Dexamethasone for responding patients following 4 cycles of induction chemotherapy
Study: NCT02316782

Intervention type: DEVICE
Intervention: Blinded IVUS assessment
Description: Only the angiogram is used for stent placement
Study: NCT01760083

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biolimus-eluting stent implantation
Description: Recanalization of chronic coronary artery occlusion and subsequent implantation of one or ore Biosensor stents
Study: NCT02396836

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 6 step technique
Description: Hand decontamination with alcohol hand rub using the World Health Organizations 6 step technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 step technique
Description: Hand decontamination with alcohol hand rub using the 3 step technique
Study: NCT02350309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 5 mg
Description: Lemborexant 5 mg tablet.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg
Description: Lemborexant 10 mg tablet.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lemborexant-matched placebo.
Description: Lemborexant-matched placebo tablet.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flurazepam 30 mg
Description: Flurazepam 30 mg capsule.
Study: NCT03033407

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tailored mobile coaching messages
Description: Intervention was adding tailored mobile coaching to current usual diabetes care. The participants received regular mobile messages via Switch app according to entered data, such as self-monitoring of blood glucose, blood pressure, exercise, dietary record, medication record, and body weight. Contents of messages were alert for the unused, weather, behavioral recommendation, education about diabetes, and individualized advices.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored mobile coaching messages
Description: Intervention was adding tailored mobile coaching to current usual diabetes care. The participants received regular mobile messages via Switch app according to entered data, such as self-monitoring of blood glucose, blood pressure, exercise, dietary record, medication record, and body weight. Contents of messages were alert for the unused, weather, behavioral recommendation, education about diabetes, and individualized advices.
Study: NCT02316782

Intervention type: DEVICE
Intervention: Nonblinded IVUS
Description: Angiogram, Grayscale IVUS and VH IVUS used for stent placement pre and post intervention
Study: NCT01650363

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture, homeopathy, osteopathy- and reflexology
Description: a combination of the above mentioned treatments

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Homeopathic placebo medication
Description: 2-3 mm small spheric suger pils
Study: NCT04027166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Methadone will be administered before study procedures

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone
Description: Methadone will be delayed (4 hours) until the end of the procedures
Study: NCT00531843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fondaparinux sodium
Description: fondaparinux 2.5mg SubQ daily for DVT prophylaxis to be started by treating physicians once deemed safe and to be discontinued once patient in discharged from the hospital or at discretion of treating physicians.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fondaparinux sodium
Description: fondaparinux 2.5mg SubQ daily for DVT prophylaxis to be started by treating physicians once deemed safe and to be discontinued once patient in discharged from the hospital or at discretion of treating physicians.
Study: NCT04276493

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zanidatamab
Description: Administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Zanidatamab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Administered intravenously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Administered orally
Study: NCT00531843

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sequential compression devices
Description: Sequential compression devices at all times during the patient's hospital admission will be used in patients who have a contraindication to pharmacologic DVT prophylaxis. This is already the current standard of care.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sequential compression devices
Description: Sequential compression devices at all times during the patient's hospital admission will be used in patients who have a contraindication to pharmacologic DVT prophylaxis. This is already the current standard of care.
Study: NCT01322347

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Standard dialysate
Description: Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week.
Study: NCT04276493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Administered intravenously
Study: NCT04528680

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonication for opening of blood-brain barrier
Description: Implantation of SC-9 device and repeat activation of 9 ultrasound emitters during i.v. injection of microbubbles
Study: NCT04300556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Farletuzumab ecteribulin
Description: Farletuzumab ecteribulin intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Farletuzumab ecteribulin
Description: Farletuzumab ecteribulin intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Farletuzumab ecteribulin
Description: Farletuzumab ecteribulin intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Farletuzumab ecteribulin
Description: Farletuzumab ecteribulin intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Farletuzumab ecteribulin
Description: Farletuzumab ecteribulin intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Farletuzumab ecteribulin
Description: Farletuzumab ecteribulin intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Farletuzumab ecteribulin
Description: Farletuzumab ecteribulin intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone administered orally.
Study: NCT04408105

Intervention type: BEHAVIORAL
Intervention: Primary Care Provider Survey
Description: To assess PCP demographics, attitudes, and perceived barriers to BE screening, we have developed a PCP survey using a theoretical model of physician behavior based on Social Cognitive Theory and the Theory of Reasoned Action. This approach has proven effective in colorectal cancer and hepatocellular carcinoma screening. This model includes domains of provider background and experience, screening practices, perceptions of screening, physician influences, and practice environment and practice patterns. To assess PCP knowledge of BE screening, we have designed 9 clinical vignettes that will categorize provider responses into under-, appropriate, and over-use of BE screening. Survey questions and vignettes have been adapted from earlier validated surveys. Prior to distribution, the survey and vignettes will be pretested and refined based on a cognitive interview about the survey among a convenience sample of 10 PCPs.

Intervention type: BEHAVIORAL
Intervention: Gastroenterologist Survey
Description: To assess GI demographics, attitudes, and perceived barriers to BE screening, we have developed a GI survey using a theoretical model of physician behavior based on Social Cognitive Theory and the Theory of Reasoned Action. This approach has proven effective in colorectal cancer and hepatocellular carcinoma screening. This model includes domains of provider background and experience, screening practices, perceptions of screening, physician influences, and practice environment and practice patterns. To assess GI knowledge of BE screening, we have designed 9 clinical vignettes that will categorize provider responses into under-, appropriate, and over-use of BE screening. Survey questions and vignettes have been adapted from earlier validated surveys. Prior to distribution, the survey and vignettes will be pretested and refined based on a cognitive interview about the survey among a convenience sample of 10 GIs.

Intervention type: BEHAVIORAL
Intervention: Patient Survey
Description: To assess patient knowledge, attitudes, and barriers to completion of BE screening, we will use a theoretical model of patient behavior on the Health Behavior Framework to guide selection of relevant variables for survey development including 4 domains: knowledge about BE and EAC, potential barriers to BE screening completion, patient attitudes and demographic information. Prior to distribution, the survey will be refined and pretested among a sample of 10 patients with each participant completing a cognitive interview prior to distribution.
Study: NCT02766699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR(V)-EDV-Dox
Description: EGFR(V)-EDV-Dox using EnGeneIC EDV™ technology is a bacterially derived minicell which packages a toxic payload, Doxorubicin, into a 400 nm particle which targets specific cancer cells using bispecific antibodies (BsAb). BsAb-targeted, payload-packaged EDV nanocells only exit the leaky blood vessels associated with tumors and enter into the tumor microenvironment. The BsAb binds to the tumor cell-surface receptor, where the EDV is taken up, broken down within the cancer cell and releases the Doxorubicin. The residual EDVs that do not make it into the tumor microenvironment, are engulfed by cells of the immune system and since the EDVs are derived from bacteria, they carry potent immuno-stimulating components which appear to bypass the immuno-suppression caused by the tumor.
Study: NCT03682471

Intervention type: DRUG
Intervention: Deoxycholic acid Injection
Description: Solution for subcutaneous injection.

Intervention type: DRUG
Intervention: Deoxycholic acid Injection
Description: Solution for subcutaneous injection.

Intervention type: DRUG
Intervention: Placebo
Description: Placebo, 10 mM sodium phosphate, 0.9% \[w/v\] sodium chloride in water for subcutaneous injection.
Study: NCT02399137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-Paclitaxel
Study: NCT00632554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone 0.5 mg/kg/day for three months
Description: period of treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisolone 0.5 mg/kg/day for six months
Description: period of therapy
Study: NCT04915391

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin biopsy and blood sample for inflammation markers, RNA and proteins
Description: A skin biopsy will be performed at the baseline visit from which primary cell cultures of fibroblasts and keratinocytes will be obtained. Four to six weeks later a second biopsy on the scar will be performed and analyzed anatomically and pathologically. In addition, at the initial visit, blood samples will be drawn for analysis of inflammation markers, RNA and proteins.

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin biopsy and blood sample for inflammation markers, RNA and proteins
Description: A skin biopsy will be performed at the baseline visit from which primary cell cultures of fibroblasts and keratinocytes will be obtained. Four to six weeks later a second biopsy on the scar will be performed and analyzed anatomically and pathologically. In addition, at the initial visit, blood samples will be drawn for analysis of inflammation markers, RNA and proteins.
Study: NCT02903667

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bone grafting

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Bone grafting